TriSalus Life Sciences Secures Up to $50M in Debt Financing from OrbiMed for TriNav® Infusion System Growth
TriSalus Life Sciences Inc. (Nasdaq: TLSI) has finalized a debt financing agreement of up to $50 million with OrbiMed, a leading healthcare investment firm. This capital infusion aims to offer financial flexibility, enabling the company to execute strategic expansion initiatives…
Axonics Q1 2024 Financial Report
Axonics, Inc. (Nasdaq: AXNX), a medical technology firm specializing in innovative and minimally invasive products for bladder and bowel dysfunction treatment, announced its financial results for the three months ending March 31, 2024. “Our commercial team maintained exceptional performance in…
ATLATL Scientific and Miltenyi Biotec Forge 5-Year Biotech Innovation Partnership
ATLATL Scientific and Miltenyi Biotec mark a significant milestone with their five-year partnership, showcasing a journey of collaboration and innovation in the biotech sector. This dynamic alliance has flourished, driving notable advancements in biotechnology. Since its inception, the partnership has…
ICON Announces Pricing of USD 2 Billion Notes
ICON plc (NASDAQ: ICLR), a top-tier healthcare intelligence and clinical research organization, has announced the pricing of a $2 billion SEC-registered bond offering. The offering includes $750 million 5.809% Senior Secured Notes due 2027, $750 million 5.849% Senior Secured Notes…
OACHC and AndHealth Collaborate for Specialty Care + Pharmacy in Ohio Community Health Centers
AndHealth has teamed up with the Ohio Association of Community Health Centers (OACHC) to introduce a statewide Whole-Person Community Care Model for Ohio’s Community Health Centers (CHCs) and their patients. With this partnership, Ohio’s 59 CHCs, constituting the state’s largest…
Reimagine Care Expands Clinical Advisory Board for Cancer Care Innovation
Reimagine Care, a leading provider of virtual-first cancer care, is excited to announce the growth of its Clinical Advisory Board. Renowned healthcare professionals specializing in cancer care have joined the board, bringing valuable expertise across the entire cancer spectrum. With…
Merrimack Pharma Plans Voluntary NASDAQ Delisting Pending Stockholder Approval for Dissolution
Merrimack Pharmaceuticals (NASDAQ: MACK) has notified NASDAQ of its intention to delist its securities, pending stockholder approval of the Plan of Dissolution at the scheduled Special Meeting on May 10, 2024. The plan entails issuing an initial liquidating cash dividend…
Heidelberg Engineering Advances Imaging with Research Tech
Heidelberg Engineering invites ARVO delegates to explore its cutting-edge imaging technology across various applications, spanning from fundamental vision research to clinical trials and guided therapy. These advancements, rooted in diagnostic imaging excellence, aim to enhance patient care by revealing deeper…
Emtora Data in Spotlight at 2024 Digestive Disease Week
Emtora Biosciences, Inc., a San Antonio-based biotech firm, has announced the acceptance of an abstract for oral presentation at the upcoming Digestive Disease Week Annual Meeting. This prestigious event gathers professionals in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery worldwide. Dr.…
Locate Bio Secures £9.2M for LDGraft Clinical Study
Locate Bio, an innovative orthobiologics firm, has concluded an oversubscribed £9.2 million funding round with support from new and existing investors, including Mercia Ventures and BGF. The funding will facilitate a clinical study for LDGraft, a bone graft substitute designed…
MiLaboratories, Miltenyi Biotec Forge Therapeutic Partnership
MiLaboratories, renowned for RNA immune technologies, and Miltenyi Biotec, a global biotechnology leader, join forces in a groundbreaking partnership set to transform next-generation therapies. This collaboration merges MiLaboratories’ innovative RNA kit technology for immune sequencing with Miltenyi Biotec’s extensive production…
ENHERTU® Shows Promising Results in Breast Cancer Trial
The top-line findings from the DESTINY-Breast06 phase 3 trial reveal a significant advancement with ENHERTU® (trastuzumab deruxtecan). Compared to standard chemotherapy, ENHERTU demonstrated both statistically and clinically significant enhancements in progression-free survival (PFS) for patients with HR positive, HER2 low…